Links

Homepage

Stock List

Search by Ticker

News

Login

Genetic Technologies Ltd (NasdaqCM:GENE)
Stock Analysis

GENE3.92
▼ -3.45%-0.14

Stock Analysis

The following stock analysis is based on 7.5 years of data (i.e. since Feb 19, 2013). All the stock history has been downloaded.

Stock Exchange

Genetic Technologies Ltd trades on the NasdaqCM exchange in USD dollars.

Sector

It is in the healthcare sector.

Current Status of Genetic Technologies Ltd

It is currently trading at $3.92 ($4.06 the previous day).

Financials

The next reporting date is in -18481 days (1970 01 01).

The current Canada / US exchange rate is 1.33061.



Will This Trend Continue?

The year over year average increase is -19.6% per year assuming steady exponential growth. The actual 5 year average is 7.02. Details on the individual increase in one year intervals is provided below.

Past PerformanceAverage PricePercent Change
1 year2.6351870967742184.7+ Above Average
2 year0.9257576744186-20.4- Below Average
3 year1.1632217573222-12.2- Below Average
4 year1.3255060728745-85.6- Below Average
5 year9.2261132075472-31.4- Below Average
Genetic Technologies Ltd is projected by analysts to get to $25.65 within the next 12 months (554.3%), but preticted targets range from as high as $25.65 (554.3%) and as low as $25(537.8%).

Risk

The worst drop it has had in recent years is -99.2%. It has a dropping shape to the stock curve, which means the stock has to be watched closely. If the financials are good, it could be very profitable, however if not it may not recover and should be sold.

Stock shape test

DAYS AG0PRICE
104.09DROPPING
302.41RISING
602.01RISING
1502.92DROPPING
3650.5501RISING
8001.17DROPPING
12001.14RISING
16008.92DROPPING
200032.16DROPPING


Tradingview BuySell Widget

Yahoo News Feed

Genetic Technologies Announces Closing of $5.1 Million Registered Direct Offering

Tue, 21 Jul 2020 00:30:10 MELBOURNE, Australia, July 20, 2020 -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests,.... Read Full Article

Genetic Technologies Announces $5.1 Million Registered Direct Offering

Thu, 16 Jul 2020 12:02:42 MELBOURNE, Australia, July 16, 2020 -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests,.... Read Full Article

Genetic Technologies Provides Update on COVID-19 Disease Severity Test

Wed, 15 Jul 2020 12:00:10 Highlights Genetic Technologies has filed a provisional patent for its COVID-19 Severity Risk Test with the Patent Office in AustraliaThe COVID-19 Severity Risk Test.... Read Full Article

Genetic Technologies CEO to Participate in Investor Webinar and QandA Session on June 24, 2020

Tue, 23 Jun 2020 12:00:10 MELBOURNE, Australia, June 23, 2020 -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”) is pleased to announce that its.... Read Full Article

US Patent Office Grants Key Risk Test Patent

Thu, 18 Jun 2020 12:00:10 Issuance of US Patent No: US 10,683,549, Methods for assessing risk of developing breast cancer.Filed provisional patent for its COVID-19 Severity Risk Test, 2020901739 –.... Read Full Article

Insider Buying: The Genetic Technologies Limited (ASX:GTG) Independent Non-Executive Chairman Just Bought 24% More Shares

Thu, 04 Jun 2020 20:49:01 Potential Genetic Technologies Limited (ASX:GTG) shareholders may wish to note that the Independent Non-Executive...... Read Full Article

Genetic Technologies Announces Closing of $8.0 Million Public Offering

Fri, 29 May 2020 01:00:10 Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today announced the closing of its previously announced public offering of 3,500,000 American Depositary Shares (“ADSs”), each representing six hundred (600) of the ...... Read Full Article

Genetic Technologies Announces Pricing of $8.0 Million Public Offering

Tue, 26 May 2020 13:22:07 Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today announced that it has priced a public offering of 4,000,000 American Depositary Shares (“ADSs”) (or ADS equivalents), each representing six hundred (600) ...... Read Full Article

Genetic Technologies Provides Operational Update - Successful Prototype Polygenic Risk Score for COVID-19 Created

Fri, 22 May 2020 20:05:10 To accompany that process, the Company will be working with its Consumer Initiated Testing (CIT) platform supplier to generate online product content to support sales activities in the USA. Leveraging Genetic Technologies’ core expertise in predictive risk modelling, the Company ...... Read Full Article

Genetic Technologies - Accelerated development of new COVID-19 Polygenic Risk Test for Risk of Developing Life-Threatening Complications

Wed, 20 May 2020 13:15:10 Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is to commence accelerating development of a polygenic risk score (PRS) test to predict an individual’s risk of developing life-threatening complications should they become infected with COVID-19. Dr George Muchnicki CEO said "...... Read Full Article

COVID-19 Testing Capacity at Genetic Technologies Accredited Laboratory

Fri, 17 Apr 2020 12:00:10 Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”) has developed a detailed implementation plan to enable a temporary transition of our genetic testing laboratory to a high-throughput COVID-19 testing laboratory, should it be required by Government agencies to assist ...... Read Full Article

Genetic Technologies Limited Announces Market Update on Sales, Early Test Results and Launch of Consumer Initiated Testing

Wed, 01 Apr 2020 13:00:10 Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”), provides the following update to the market. Breast Cancer and Colorectal Cancer tests commissioned, and sales commenced First Quarter 2020 with over 100 test kits distributed.... Read Full Article

Genetic Technologies Limited Announces Receipt of Delisting Notification Letter from Nasdaq

Sat, 14 Mar 2020 00:15:10 The Letter indicates that Listing Rule 5815(d)(4)(B) does not permit an issuer that is deficient in stockholders’ equity to present a plan of compliance to the Nasdaq Staff if such issuer has failed to comply with that provision within ...... Read Full Article

Those Who Purchased Genetic Technologies (ASX:GTG) Shares Five Years Ago Have A 82% Loss To Show For It

Thu, 12 Mar 2020 23:35:32 While it may not be enough for some shareholders, we think it is good to see the Genetic Technologies Limited...... Read Full Article

Genetic Technologies to provide Corporate and Strategic Update at 2020 Biotech Showcase

Mon, 13 Jan 2020 14:00:10 MELBOURNE, Australia, Jan. 13, 2020 -- Genetic Technologies (ASX: GTG; NASDAQ: GENE), a leader in the development of genetic risk assessment tests, recently announced the.... Read Full Article

20 Medical centers across 8 US states set to offer Breast Cancer Test

Tue, 07 Jan 2020 16:45:10 Molecular diagnostics company Genetic Technologies Limited (ASX: GTG, NASDAQ: GENE) is pleased to advise that its third-generation breast cancer test (GeneType for Breast Cancer) is on track for commercial release in the Unites States (US) in Q1 2020. Genetic Technologies expects ...... Read Full Article
<